Hitiq Limited · ASX:HIQ
Hitiq — Investor Presentation (November 2022)
27 slides from Hitiq's investor presentation, Nov 28, 2022
Slide 1: Bell Potter Broker Presentation
Bell Potter Broker Presentation 28 November 2022 advanced concussion management
Slide 2: Important Notice and Disclaimer
Disclaimer 2 IMPORTANT NOTICE AND DISCLAIMER This presentation has been prepared by HITIQ Limited (HIQ) and is provided for general information purposes only. No party other than HITIQ has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, represen
Slide 3: Highlights: Compelling opportunity with large potential upside
Highlights 3 Compelling opportunity with large potential upside. ► Corporate Re-set, with recapitalisation underway @ ~ $3.5m Enterprise Value. New Aim of cashflow break-even within 18 months, via cost cutting and continued strong revenue growth, particularly in the consumer market. ► Global Leader
Slide 4: Corporate Summary and Capital Structure
Capital Structure 4 Corporate Summary. Capital Structure (23 November 2022) Shareholders ASX Code HIQ Top 20 Shareholders 36% Share Price $0.031 15% Shares on Issue 132.4 M Directors and Management Top 20 Unlisted Options ($0.20 to mainly $0.30 ~25.7 M 64% 36% Others Market Capitalisation $4.1M Cash
Slide 5: Renounceable Rights Issue Offer
Capital Raising 5 Renounceable Rights Issue Offer. KEY DETAILS OF THE OFFER > 8 New Shares for every 5 Shares held at the Record Date at the Issue Price plus; > 1 Option for every 1 New Share subscribed under the Offer. Offer to Eligible Shareholders > Option means a New Option to purchase a Share w
Slide 6: Use of Funds
Capital Raising 6 Use of Funds. The proposed capital raise will: Sales & marketing of consumer facing product suite $0.70m ► Progress commercialisation activities Further development technology platform including within the consumer market. $1.9m virtual reality pre-clinical activities ► Assist in l
Slide 7: Timetable
Capital Raising 7 Timetable. Indicative Rights Issue Timetable1 Event Date Rights Issue announcement and company resumes trading Tuesday, 1 November 2022 Record Date Thursday, 10 November 2022 Dispatch of Prospectus and Rights Issue Offer opens Monday, 14 November 2022 Rights trading ends at close o
Slide 8: Capital Raising Summary: Deal Structure
Capital Raising Summary 8 Deal ~ $3.5m Enterprise $6.3m Structure Valuation (EV) Raise Renounceable Rights Transaction implies an Use of funds to grow Issue. enterprise value of revenues in consumer & elite ~$3.5m. segments as well as bring virtual reality technology to clinical trial. 8 New Shares
Slide 9: Market Traction
Market Traction 9 Trusted by the largest sporting codes & leagues across the globe to deliver highly “Football is an evolving sport, I am pleased that HITIQ's technology is improving our ability to quantify our valuable data. athletes head impacts.” BRETT MORTENSEN Brigham Young University Rehab Coo
Slide 10: Near Term Catalysts
Future Value Inflection Points 10 Near Term Catalysts REVENUE GROWTH (1HFY’23 on track to be just below FY’22) 01 ✓ Expand consumer sales footprint, growing consumer market revenues (school and community sports / potential Shock Doctor collaboration in ‘boil & bite market’). ✓ Growth of elite market
Slide 11: Technology & Company Overview
Technology & Company Overview
Slide 12: Key Investor Highlights
Key Investor Highlights 12 Unique world leading technology stack End-to-end multi product platform addressing unmet global concussion strategy to facilitate social responsibility management opportunity. & player well being for administrators. Most diverse and comprehensive S t r a t e g i c p a r t
Slide 13: End-to-end data strategy underpinning our competitive moat
Competitive Differentiator 13 End-to-end data strategy promotes a “care journey”, underpinning our competitive moat. The mission is to: 1. Eliminate risk of acute concussions being undetected & undiagnosed; and 2. Ensure the monitoring of potential longer-term effects related to the accumulation of
Slide 14: World's first commercial end-to-end brain injury management platform
Strategy 14 World’s first commercial end-to-end brain injury management platform. Three pillar strategy driving our end-to-end vision. three related pillars 01 Surveillance & 02 Assessment, 03 Rehabilitation Detection Monitoring & Diagnosis Quantify Specific retraining & Impact Loads. Define Impairm
Slide 15: One technology platform targets all components of the end-to-end journey
Solution 15 One technology platform provides opportunity to target all components of end-to-end journey. Surveillance Digital Virtual Reality System Assessment Tool Diagnostic Aid Sensor technology embedded into Leading concussion assessment Immersive test protocol within virtual mouth guards to cap
Slide 16: Product 1: Nexus Surveillance System
Product 1; Nexus Surveillance System 16 HITIQ is the Global Leader in impact sensor technology. 98% System Accuracy. Purpose built form factor. Only valid method to obtain accurate brain impact data, due to positioning of impact sensors near the brain. +3k Units in Elite Market Globally. Independent
Slide 17: Strong Consumer Go-to-Market Strategic Partnerships for Nexus
Nexus Surveillance System 17 Strong Consumer Go-to-Market Strategic Partnerships for Nexus. Partnership to deliver technology into grass roots through the largest health insurer in Australasia. Providing subsidy to customers through existing health insurance policies. ► 257 dental clinics within Aus
Slide 18: CSX Digital Assessment Tool
CSX Digital Assessment Tool 18 Electronic record for standardised concussion CSX assessment protocols. Vast databank of baseline and Head Impact Assessments (HIA) performed. Thousands of brains under management via the CSX platform. Critical compliance and digital record keeping tool for clinicians.
Slide 19: Strong adoption from Elite Market to launch CSX community platform
CSX Digital Assessment Tool 19 Strong adoption from Elite Market to help launch CSX community platform in CY’23. CSX Current concussion management protocols in the community face the following challenges: ➢ The standard of care provided by general practitioners is extremely varied and mostly inept.
Slide 20: CoVR Technology Background: Entry into emerging technology sector
CoVR Technology Background 20 Entry into an emerging technology sector, opening access to a lucrative diagnostic market. Test protocol utilises an array of proprietary mini games designed for robust assessment of the various cognitive abilities that can be adversely affected by concussion. Pre-clini
Slide 21: New approach for cognitive assessment
CoVR Technology Background 21 New approach for cognitive assessment. Migrates traditional paper and subjective evaluations to a more sophisticated level and enhanced sensitivity. System provides robust assessments that can assess cognitive skills in a more standardised, objective & reproducible mann
Slide 22: CoVR Regulatory Pathway: Clinical Validation Pathway
CovR Regulatory Pathway 22 Clinical Validation Pathway. Complete Complete In Progress Prototype Review, Testing Regulatory System Validation Pre-Clinical Clinical Approval & Development Testing Trial Testing Trial Launch Study 1 - Normative Data. Study 5 - Internal Validity v2. Study 2 - Construct V
Slide 23: Strong building blocks of IP Portfolio
Positioning 23 Strong building blocks of IP Portfolio. Total Applications Provisional PCT National applications (15) (6) Fillings (32) Filed Current International Australia United States Europe NZ Canada Global (2) (19) (7) (5) (1) (1) Coverage Examination Patent Examination Awaiting Examination Und
Slide 24: Well positioned for growth across multiple sectors
Positioning 24 Well positioned for growth across multiple sectors. Technology Suite Consumer Growth Offering Pathways Established Robust R&D phase has delivered a Established partner portfolio to facilitate strong entry into scientifically validated technology consumer segment within local and inter
Slide 25: Addressable Market
Addressable Market 25 We're targeting a growing worldwide concussion-brain injury market including elite and community sport, & allied health segments. Accounts Athletes Nexus CSX CoVR HITIQ has established a ELITE SPORT 10k 500k $310m $28m $100m data subscription model Tier 1 for its integrated har
Slide 26: Team
Team 26 BOARD OF DIRECTORS SCIENTIFIC & MEDICAL ADVISORY COUNCIL Honorary Associate Emeritus Professor Otto Buttula Aidan Clarke Glenn Smith Phil Carulli Professor Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Jeffrey V. Rosenfeld Andrew Gardner AC OBE E
Slide 27: End
End 27 empowering advanced concussion management - ENDS - Authorised for release by the Chairman & Managing Director. Mike Vegar Elvis Jurcevic CEO & MD Investor Relations HITIQ Limited +61 408 268 271 investors@hitiq.com ej@hitiq.com